Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Summary

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Acute Leukemia
• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Adult Diffuse Large Cell Lymphoma
• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Chronic Myeloid Leukemia, BCR-ABL1 Positive
• Chronic Myelomonocytic Leukemia
• Hodgkin Lymphoma
• Lymphoblastic Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndrome
• Prolymphocytic Leukemia
• Refractory Chronic Lymphocytic Leukemia
• Refractory Follicular Lymphoma
• Refractory Marginal Zone Lymphoma
• Refractory Small Lymphocytic Lymphoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

6 months and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Fred Hutchinson Cancer Center

Last updated on ClinicalTrials.gov

May 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites